Vivos Therapeutics Inc 2025年季度报告

FORM10-Q TABLE OF CONTENTS Item 1.Legal Proceedings44Item 1A.Risk Factors45 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” (as defined in Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that reflect our currentexpectationsand views of future events.The forward-looking statements are contained principally in the section entitled“Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Readers are cautioned that known andunknown risks, uncertainties and other factors, including those over which we may have no control and others listed in this Report and You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,”“aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. We have basedthese forward-looking statements largely on our current expectations and projections about future events that we believe may affect ●our ability to continue to refine and execute our evolving business plan, including establishing and growing our newsales, marketing and distribution model where we acquire or create contractual alliances with operators of sleeptesting and treatment centers as a means of driving sales of our appliances, including our June 2025 acquisition ofThe Sleep Center of Nevada (“SCN”);●our ability to implement and grow our sales, marketing distribution model, which is new and unproven and may notproduce the benefits we anticipate;●our ability to successfully integrate SCN business into our operations; ●our ability to service the substantial indebtedness we incurred in connection with financing the SCN acquisition; compliance with laws, rules and regulations relating to the corporate practice of medicine; ●the viability of our current intellectual property and our ability to create and protect new intellectual property in thefuture;●acceptance of our products and services by the medical and dental communities, as well as the marketplace of theproducts and services that we market;●government regulations and our ability to obtain applicable regulatory approvals and comply with governmentregulations including under healthcare laws and the rules and regulations of the FDA and non-U.S. equivalentregulatory bodies;●our ability to hire and retain key employees and other service providers (including dentists or other healthcareproviders);●the emergence of alternative technologies, devices, drugs or other therapies which directly or indirectly impact themarketability of our products and services;●adverse changes in general market conditions for medical devices and the products and services we offer;●our ability to generate cash flow and profitability and continue as a going concern;●our future financing plans; and●our ability to adapt to changes in market conditions (including volatile and difficult to access capital markets) whichcould impair our operations and financial performance. These forward-looking statements involve numerous risks and uncertainties. Although we believe that our expectationsexpressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results ofoperations or the results of other matters that we anticipate herein could be materially different from our expectations. Important risksand factors that could cause our actual results to be materially different from our expectations are generally set forth in “Management’sDiscussion and Analysis of Financial Condition and Results of Operations” “Business” and other sections in this Report as well as the The forward-looking statements made in this Report relate only to events or information as of the date on which thestatements are made in this Report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made PART I – FINANCIAL INFORMATION VIVOS THERAPEUTICS INC.Notes to Unaudited Condensed Consolidated Financial Statements NOTE 1 -ORGANIZATION, DESCRIPTION AND SIGNIFICANT ACCOUNTING POLICIES Organization BioModeling Solutions, Inc. (“BioModeling”) was organized on March 20, 2007 as an Oregon limited liability company, andsubsequently incorporated in 2013. On August 16, 2016, BioModeling entered into a share exchange agreement (the “SEA”) with FirstVivos, Inc. (“First Vivos”), and Vivos Therapeutics, Inc. (“Vivos”), a Wyoming corporation established on July 7, 2016 to facilitate theSEA transaction. Vivos was formerly named Corrective BioTechnologies, Inc. until its name changed on September 6, 2016 to VivosBiotechnologies and on March 2, 2018 to Vivos Therapeutics, Inc. and had no subst